‘Zydus Cadila agreed to cut vaccine price to Rs 265 per dose’
The three dose DNA built vaccine has 66.6 per cent efficacy against Covid, says manufacturer Zydus Cadila.
Drugs Controller General of India (DGCI) has given its approval for emergency use for Zydus Cadila’s Pegylated Interferon alpha-2b, “Virafin” for treating moderate COVID-19 infection in adults.
“The fact that we are able to offer a therapy which significantly reduces viral load when given early on can help in better disease management. It comes at a much-needed time for patients and we will continue to provide them access to critical therapies in this battle against COVID-19.” Dr Sharvil Patel, Managing Director, Cadila Healthcare Limited said.
Advertisement
India recorded 3,32,730 new coronavirus cases in the last 24 hours, setting yet another grim one-day record, taking the overall caseload to 1,62,63,695, according to data from the Union Health Ministry.
Advertisement
The country’s active COVID-19 cases stand at 24,28,616.
Advertisement
